Several biotech companies are advancing novel cancer treatments through clinical development. Oncolytics Biotech received FDA Fast Track Designation for pelareorep in KRAS-mutant colorectal cancer, showing doubled survival benefits. Novocure gained FDA approval for Optune Pax for pancreatic cancer. Perspective Therapeutics presented positive interim data for its radiopharmaceutical VMT-α-NET. ImmunityBio launched a Phase 2 trial for its CAR-NK cell therapy combined with IL-15 superagonist. Nuvation Bio expanded its Phase 3 trial for safusidenib in IDH1-mutant glioma.

Soleus Capital Management increased its stake in Celcuity by 629,398 shares, bringing its total holdings to over 1.8 million shares valued at $180.36 million. This purchase elevated Celcuity to Soleus's third-largest holding, representing 6.7% of the fund's AUM. The move signals bullish confidence in the clinical-stage biotech company, which has seen its stock surge 745% over the past year.

The FDA has approved Optune Pax, a portable non-invasive device developed by Novocure that delivers tumor treating fields (TTFields) to treat locally advanced pancreatic cancer. The device, which received Breakthrough Device designation, showed approximately two months improvement in overall survival when combined with standard chemotherapy in clinical trials.

U.S. stock futures rose on Thursday following a strong January jobs report showing 130,000 jobs added, exceeding expectations. The report dampened rate cut expectations, with markets pricing in only a 6% chance of a March rate cut. Key movers include Micron (up 3.3%), Novocure (up 33% on FDA approval), and Fastly (up 43% on strong earnings), while AppLovin fell 4.95% despite beating expectations.

Novocure announced positive results from its Phase 3 METIS trial, demonstrating that Tumor Treating Fields (TTFields) therapy can significantly delay brain metastasis progression in non-small cell lung cancer patients without causing neurocognitive side effects.

Wall Street analysts are bullish on Viking Therapeutics and NovoCure, two healthcare stocks with significant potential growth despite recent market challenges in their clinical trials and product launches.

Novocure reported 6% revenue growth and 9% patient growth, with plans to seek FDA approval for pancreatic and brain cancer treatments. Despite not being profitable, the company maintains significant cash reserves and potential for future development.

NovoCure, a leader in oncology treatments using Tumor Treating Fields (TTFields) therapy, reported strong Q1 2025 results with revenue and GAAP earnings surpassing estimates. The company saw robust patient growth and progress in clinical trials, though challenges in gross margins remain.

NovoCure, a cancer-focused biotech company, saw its stock price drop after an analyst reduced its price target, despite the change being relatively small. The market is hungry for good news from NovoCure, but as a biotech company, it requires time and resources to bring its products to market.

NovoCure, a cancer-targeting biotech company, reported positive results from a phase 3 clinical trial of its tumor treating fields (TTF) therapy. The therapy demonstrated a statistically significant improvement in survival for patients with unresectable, locally advanced pancreatic adenocarcinoma. Analysts were encouraged by the results and raised their price targets on the stock.

NovoCure, a cancer-focused biotech company, saw its share price decline by over 13% over a holiday-shortened trading week due to a series of C-suite changes, including the departure of its long-serving CEO Asaf Danziger and COO Wilco Groenhuysen.

7 analysts have shared their evaluations of NovoCure (NASDAQ:NVCR) during the recent three months, expressing a mix of bullish and bearish perspectives. The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 2 5 0 0 Last 30D 0 0 1 0 0 1M Ago 0 0 0 0 0 2M Ago 0 1 1 0 0 3M Ago 0 1 3 0 0 Analysts have recently evaluated NovoCure and provided 12-month price targets. The average target is $25.29, accompanied by a high estimate of $42.00 and a low estimate of $17.00. This current average has decreased by 3.36% from the previous average price target of $26.17. Deciphering Analyst Ratings: An In-Depth Analysis A comprehensive examination of how financial experts perceive NovoCure is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Emily Bodnar HC Wainwright & Co. Maintains Neutral $22.00 $22.00 Emily Bodnar HC Wainwright & Co. Lowers Neutral $22.00 $24.00 Jason Bednar Piper Sandler Raises Overweight $28.00 $25.00 Larry Biegelsen Wells Fargo Lowers Overweight $42.00 $49.00 Emily Bodnar HC Wainwright & Co. Raises Neutral $24.00 $22.00 Jessica Fye JP Morgan Raises Neutral $17.00 $15.00 Emily Bodnar HC Wainwright & Co. Maintains Neutral $22.00 - Key Insights: Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, ...Full story available on Benzinga.com